NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.57) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.02. View Avrobio's Earnings History.

Avrobio is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Avrobio.

7 brokerages have issued 1 year target prices for Avrobio's stock. Their forecasts range from $24.42 to $43.00. On average, they anticipate Avrobio's share price to reach $36.24 in the next year. This suggests a possible upside of 59.3% from the stock's current price. View Analyst Price Targets for Avrobio.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.

Media stories about AVRO stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avrobio earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Avrobio.

Avrobio saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 706,400 shares, a drop of 56.1% from the January 15th total of 1,610,000 shares. Based on an average daily volume of 183,200 shares, the short-interest ratio is presently 3.9 days. Currently, 3.2% of the company's stock are short sold. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), Beam Therapeutics (BEAM), I-Mab (BDTX), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX) and BAVARIAN NORDIC/S (BVNRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), Aduro BioTech (ADRO), Amarin (AMRN), Crispr Therapeutics (CRSP), Exelixis (EXEL), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE), Biohaven Pharmaceutical (BHVN) and Abeona Therapeutics (ABEO).

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (3.16%), Emerald Advisers LLC (2.07%), State Street Corp (2.03%), Victory Capital Management Inc. (1.41%), Victory Capital Management Inc. (1.32%) and Geode Capital Management LLC (0.93%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.

AVRO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., UBS Group AG, AlpInvest Partners B.V., Victory Capital Management Inc., Rafferty Asset Management LLC, Bank of America Corp DE, Goldman Sachs Group Inc. and TD Asset Management Inc.. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige and Geoffrey Mackay. View Insider Buying and Selling for Avrobio.

AVRO stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Tang Capital Management LLC, FMR LLC, Parkman Healthcare Partners LLC, California Public Employees Retirement System, Spark Investment Management LLC, Nisa Investment Advisors LLC and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Avrobio.

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $22.75.

Avrobio has a market capitalization of $720.49 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.

The official website for Avrobio is http://www.avrobio.com/.

Avrobio's mailing address is ONE KENDALL SQUARE BLDG. 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]